A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ [hydrochlorothiazide] with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension.

Trial Profile

A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ [hydrochlorothiazide] with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2014

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
  • Indications Essential hypertension; Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Actual end date (July 2006) added as reported by ClinicalTrials.gov (Extension trial: NCT00294710).
    • 07 Nov 2011 Actual end date (July 2006) added as reported by ClinicalTrials.gov (Extension trial: NCT00294710).
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top